60 Degrees Pharmaceuticals(US:SXTP) Globenewswire·2025-11-13 18:51Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenue for Q3 2025, alongside challenges in gross profit due to inventory write-offs and increased operating expenses [6][7]. Financial Highlights for Q3 2025 - Net product revenue increased by 223% year-over-year to $438 thousand [6]. - Gross profit decreased from $24 thousand to a loss of $100 thousand due to a one-time inventory write-off [6][7]. - Operating expenses rose to approximately $2.32 million, up from $2.16 million in Q3 2024, primarily due to increased advertising and sales promotion costs [7]. - Net loss attributable to common shareholders was approximately $2.44 million, or ($0.66) per share, compared to a net loss of approximately $2.27 million, or ($4.65) per share in Q3 2024 [7]. Business Highlights for Q3 2025 - ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes in Q3 2024 to 1,505 boxes in Q3 2025 [7]. - The company announced its intention to seek a Minor Use Minor Species (MUMS) designation from the FDA for treating acute canine babesiosis [7]. - A nationwide survey determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035 [7]. - The company entered a sponsored research agreement with Tulane University to evaluate tafenoquine's activity against Borrelia and Bartonella bacteria [7]. - A partnership was established with the Icahn School of Medicine at Mount Sinai for a planned Phase II clinical study of tafenoquine in treating chronic babesiosis [7].